PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.

@article{Langsted2016PCSK9RL,
  title={PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.},
  author={Anne Langsted and B{\o}rge G. Nordestgaard and Marianne Benn and Anne Tybj{\ae}rg-Hansen and Pia R{\o}rbœk Kamstrup},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2016},
  volume={101 9},
  pages={
          3281-7
        }
}
CONTEXT Novel, low-density lipoprotein (LDL) cholesterol-lowering proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors also lower lipoprotein(a) levels, but the effect on aortic valve stenosis and myocardial infarction is unknown. OBJECTIVE We tested the hypothesis that the PCSK9 R46L loss-of-function mutation is associated with lower levels of lipoprotein(a) and with reduced risk of aortic valve stenosis and myocardial infarction. DESIGN We used two prospective cohort studies… CONTINUE READING
BETA